Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

CEConversations

CEConversations artwork

Emergency Care of Patients with Cancer Receiving CAR T-cell and Bispecific Antibody Immunotherapies Experiencing Serious Adverse Events

Aug 28, 202547 minAudio

As the use of immunotherapies for the treatment of cancer expands, emergency medicine (EM) clinicians will need a further understanding of their mechanisms of action (MOAs) to better guide diagnosis and treatment of patients who present to the emergency room with symptoms of adverse effects (AEs). While T-cell-retargeting therapies have revolutionized the treatment of hematological malignancies, they are also associated with symptoms of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), cytopenias, infection, and cardiotoxicity. While most cases of CRS and neurotoxicity are self-limiting and only require supportive care, some patients can progress to needing ICU care. To address these risks, EM clinicians require education on the relationship of MOAs of T-cell-directing therapies to potential AEs and improve their confidence and competence in diagnosing and treating CRS, neurotoxicity, and other toxicities associated with these agents in emergency settings. In this CE Concepts webcast, expert faculty will guide learners on how to best evaluate the effect of CAR T-cell and bispecific antibody therapies on the immune system in patients with cancer, utilize best practices for the diagnosis and management of patients receiving T-cell-directing therapies experiencing symptoms consistent with CRS, and Integrate best practices for diagnostic and management approaches for patients receiving T-cell-directing therapies experiencing AEs not consistent with CRS. Learn More: https://www.ceconcepts.com/activity/emergency-care-of-patients-with-cancer-receiving-car-t-cell-and-bispecific-antibody-immunotherapies-experiencing-serious-adverse-events/

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Webcast Finding the Right Rhythm: Supporting Pediatric Oncology Nurses in Longitudinal NF1 Management

    Oct 28, 202656 minAudio

    In this CE Concepts recorded symposium, faculty will apply NF1 diagnostic and oncologic monitoring guidelines to support early recognition of NF1-PNs in pediatric patients. Learners will be shown how to incorporate MEK...

    Credit the people on this episode

  2. Webcast: Rare, Complex, and Under-Recognized: Supporting Oncology Nurses in the Care of Patients with NF1

    Aug 6, 202652 minAudio

    Neurofibromatosis type 1 (NF1) is a rare, complex, and often under-recognized condition that presents significant diagnostic and management challenges, particularly for oncology nurses who play a central role in...

    Credit the people on this episode

  3. Evolving Paradigms in Immuno-Oncology: Optimizing Patient Care Through Innovative Delivery Approaches of Immune Checkpoint Inhibitors

    Jul 1, 202632 minAudio

    Immune checkpoint inhibitors (ICIs) have transformed the landscape of oncology, achieving remarkable outcomes across tumor types. As outcomes improve and focus shifts to patient-centered care, however, the burden of...

    Credit the people on this episode

  4. Targeting the Pathway: Evolving Roles of MEK Inhibitors in NF1-Associated PN

    Jul 1, 20261 hr 4 minAudio

    Neurofibromatosis type 1 (NF1) is a common autosomal dominant genetic disorder characterized by tumor predisposition and a wide spectrum of neurologic manifestations. Among its most serious complications are plexiform...

    Credit the people on this episode

  5. Exploring the Horizons in Advanced or Recurrent Endometrial Cancer: Practical Considerations and Future Directions for New Treatment Strategies

    Jul 1, 20261 hr 5 minAudio

    Despite significant advances in the management of advanced or recurrent endometrial cancer (EC) - including the use of molecular classification, immune checkpoint inhibitors, and targeted therapies - delivering timely,...

    Credit the people on this episode